Takeda Pharmaceutical Files 6-K for September 2024
Ticker: TKPHF · Form: 6-K · Filed: Sep 26, 2024 · CIK: 1395064
| Field | Detail |
|---|---|
| Company | Takeda Pharmaceutical Co Ltd (TKPHF) |
| Form Type | 6-K |
| Filed Date | Sep 26, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, foreign-private-issuer
TL;DR
Takeda filed a 6-K on 9/26, confirming its foreign private issuer status and reporting from Tokyo.
AI Summary
Takeda Pharmaceutical Company Limited filed a Form 6-K on September 26, 2024, to report information as a foreign private issuer for the month of September 2024. The filing indicates Takeda's principal executive offices are located in Tokyo, Japan, and confirms they file annual reports under Form 20-F.
Why It Matters
This filing serves as an update for investors regarding Takeda's regulatory reporting status as a foreign private issuer in the U.S. market.
Risk Assessment
Risk Level: low — This is a routine administrative filing confirming reporting status and location, with no new financial or operational information disclosed.
Key Players & Entities
- Takeda Pharmaceutical Company Limited (company) — Registrant
- 0001395064-24-000160 (other) — Accession Number
- 20240926 (date) — Filing Date
- Tokyo, Japan (location) — Principal Executive Offices
- Form 6-K (document) — Filing Type
- Form 20-F (document) — Annual Report Filing
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K filing is used by foreign private issuers to report information that they have made or are required to make public in their home country, or that they have submitted or are required to submit to a stock exchange on which they are listed.
What is Takeda Pharmaceutical Company Limited's filing status?
Takeda Pharmaceutical Company Limited is identified as a foreign private issuer and files annual reports under Form 20-F.
Where are Takeda's principal executive offices located?
Takeda's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo 103-8668, Japan.
What is the accession number for this filing?
The accession number for this filing is 0001395064-24-000160.
For which period is this Form 6-K reporting information?
This Form 6-K is reporting information for the month of September 2024.
Filing Stats: 606 words · 2 min read · ~2 pages · Grade level 20 · Accepted 2024-09-26 06:01:56
Filing Documents
- form6k_092624.htm (6-K) — 35KB
- 0001395064-24-000160.txt ( ) — 36KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TAKEDA PHARMACEUTICAL COMPANY LIMITED Date September 26, 2024 By s Norimasa Takeda Norimasa Takeda Chief Accounting Officer and Corporate Controller Cover Document Filed Extraordinary Report Filed with Director, Kanto Local Finance Bureau Filing Date September 26, 2024 Company Name Takeda Pharmaceutical Company Limited Title and Name of Representative Christophe Weber, Representative Director, President Chief Executive Officer Address of Head Office 1-1, Doshomachi 4-chome, Chuo-ku, Osaka (The above address is the registered head office location and the ordinary business operations are conducted at the "Nearest Place of Contact") Telephone Number Not applicable Name of Contact Person Not applicable Nearest Place of Contact 1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo (Global Headquarters) Telephone Number +81-3-3278-2111 (Main telephone number) Name of Contact Person Norimasa Takeda, Head of Global Consolidation and Japan Reporting, Global Finance Please for public inspection Takeda Pharmaceutical Company Limited (Global Headquarters) (1-1, Nihonbashi Honcho 2-chome, Chuo-ku, Tokyo) Tokyo Stock Exchange, Inc. (2-1, Nihonbashi Kabutocho, Chuo-ku, Tokyo) Nagoya Stock Exchange, Inc. (8-20, Sakae 3-chome, Naka-ku, Nagoya) Fukuoka Stock Exchange (14-2, Tenjin 2-chome, Chuo-ku, Fukuoka) Sapporo Stock Exchange (14-1, Minamiichijonishi 5-chome, Chuo-ku, Sapporo) 1 1. Reason for Submitting the Extraordinary Report The Company has submitted the Extraordinary Report pursuant to Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Law and Article 19, Paragraph 2, Item 3 of the Cabinet Office Ordinance concerning Disclosure of Corporate Affairs, etc. to report on resolution dated September 25, 2024, on a merger betwe